



Euro BioFairs Compass

Winter Edition 2017/18

LEADERSHIP

320


340

**|| Guide to Life
Sciences Events**

NW

NE

SPECIAL



26-27 APRIL 2018

16th Biosimilar Medicines Conference

**Biosimilar medicines: unlocking the full
potential of biologics**

GRANGE TOWER BRIDGE HOTEL, LONDON

On 26 and 27 April 2018, Medicines for Europe will host the 16th Biosimilar Medicines Conference in London. This year's flagship event will gather top EU and global regulators, officials, healthcare actors as well as industry leaders, to foster open exchange and debate on the role of the biosimilar medicines sector in "Biosimilar Medicines: Unlocking the Full Potential of Biologics".

THIS YEAR THE TOPIC SESSIONS WILL COVER:

- Biologic medicines ecosystem: Outlook 2030
- Optimising Access Models: Moving from problems to solution through concrete actions
 - Sustainable Procurement Practices: Experience gained in retail and hospital settings
- Caring for Patients with Cancer today and tomorrow – seizing the biosimilar medicines opportunity
 - European Medicines Agency: Key objectives for health and biosimilar medicines
 - Advancing Regulatory science
 - Ask the regulators

 **#BIOS18**



European event update

EUROBIOFAIRS COMPASS Every manager, scientist, and business developer has their own individual, specific network — and so, too, their must-attend events vary significantly. Where to meet potential new partners and how to widen one's scope beyond well-known terrain can be quite difficult to determine. Euro Biofairs Compass will help you navigate the European meeting jungle in H1/2018.

In Brussels, **MedTech Forum 2018** (23–25 January 2018), the largest medtech event in Europe, will spotlight future trends in the sector. In 2018, the event will offer new thematic tracks, more keynote sessions, and a brand new exhibition area (p. 40).

Pharmapack 2018 (7–8 February 2018) is a must-go for experts in pharmaceutical packaging, serialisation hardware and equipment, who will gather in Expo Paris (see p. 42).

The worldwide threat of antimicrobial resistance in medicine will be the focus of the 11th edition of the **Berlin Conference in Life Sciences** (2 March 2018, Fraunhofer Forum Berlin). Decision makers from Big Pharma, and biotech SMEs, policy makers, regulators, payors, business developers, and investors will meet in Berlin to explore how to incentivise companies to develop novel an-

tibiotics that can break drug resistance of multiresistant strains (see p. 44).

The sister meeting to biotech industry's largest partnering event, **EBD's Bio-Europe Spring 2018** (12–14 March), on the other hand, will provide the perfect partnering point for biotechs, investors, and pharma executives in Amsterdam (see p. 46).

For researchers in the formulation field, a visit to Berlin might be unavoidable. This year's **Nano and Micro Formulation conference** (13–14 March 2018) will present innovations in manufacturing, characterisation, and control of the next generation of nanoformulations and drug-release mechanisms (see p. 48).

A meeting with major impact kicks off on 3 May at Congress Centre Basel, which will host what has become the nation's most important biotech event,

the **Swiss Biotech Day** (3 May 2018, see p. 50). As in previous years, the new Swiss biotech report will shine a light on the industry's status in the country. Due to the growing visitor numbers (500+), the Swiss Biotech Day moved to Basel Congress Centre last year.

More than 400 exhibitors and 6,500+ visitors are expected to come to **Chem-spec Europe** (20–21 June 2018, see p. 52), Europe's premier sourcing and networking event for the fine and speciality chemicals industry. The exhibition is the central marketplace for manufacturers, suppliers, and distributors of fine and speciality chemicals to meet with purchasers and agents looking for specialised products and solutions.

Just turn the page to learn everything you need to know about Europe's must-attend events in the biotech industry. ■



a MedTech Europe event
The MedTech Forum
 bringing HealthTech stakeholders together

23–25 January, 2018
 The EGG
 Brussels, Belgium

Entering a new era

THE MEDTECH FORUM On January 23–25 2018 in Brussels, The MedTech Forum, the biggest medical technology industry event in Europe that discusses the future trends in our sector, returns with an even better on-site experience.

MedTech Europe, the association representing the in vitro diagnostic (IVD) and medical devices (MD) industry in Europe, is reshaping its annual Forum with the ambition to make it the main European medical technology event for anyone involved in medical technology in Europe. New thematic tracks, more keynote sessions, “ask the experts” roundtables and a brand new exhibition area aim at enhancing business and networking opportunities with CEOs, healthcare disruptors and key opinion leaders influencing the medtech environment. Participants will discover:

tors and key opinion leaders influencing the medtech environment. Participants will discover:

- [1] An expanded programme with world-class industry experts speaking in 40 sessions, including plenaries, CEO #nofilter discussions, keynotes and more;
- [2] A specific track for start-ups and SMEs to discuss opportunities and challenges in an evolving European financial and regulatory environment;
- [3] New business opportunities for medtech companies, service providers, start-ups, and other industry stakeholders via this year’s brand new exhibition area;
- [4] Networking opportunities to connect with fellow participants via the networking mobile app or more casually during our evening events.

The new format of The MedTech Forum offers a programme in which all health technology stakeholders will find an interest – whether in the sessions or in the networking or sponsorship opportunities.

A new vision

GREETING I’m pleased to announce that the MedTech Forum enters a new era in 2018! At MedTech Europe, the association representing the in vitro diagnostic (IVD)



and medical devices (MD) industry in Europe, we are reshaping our annual Forum with the ambition to make it **the** European medical technology event. We are driven by the objective to enlarge the program and offer a wider variety of topics, more networking opportunities and more occasions to collaborate and learn. I hope this new version of the Forum will bring you valuable insights about the new realities our industry can embrace. At the same time, we will also enlarge the target audience to a broader representation of our industry – patients, hospital representatives, service providers, suppliers, scientific societies, national associations, policymakers, notified bodies, and consultants. We will create opportunities for SMEs, start-ups and investors and find effective ways to collaborate and innovate. Together with our partners, our sponsors, our supporters and our colleagues in the sector, we can shape how the med-tech industry can be an active and reliable partner in tackling today and tomorrow’s healthcare challenges. See you in Brussels on 23–25 January 2018!

Serge Bernasconi
 CEO, MedTech Europe

› QUICK FACTS

Registration:

<http://www.themedtechforum.eu>
 MedTech Europe members benefit from special rates

Programme highlights:

- › CEO #nofilter discussions
- › Digital developments
- › Business strategies
- › Market access
- › New MD and IVD regulations



A MedTech Europe event

The MedTech Forum


bringing HealthTech stakeholders together

Join the largest
medtech industry
event in Europe

23-25 JAN.
2018
—
The EGG
BRUSSELS

#MTF2018

www.themedtechforum.eu



Drug Delivery & Packaging
Pharmapack
 INNOVATION • NETWORKING • EDUCATION

7–8 February, 2018
 Paris Expo, Porte de Versailles

The future is now

PHARMAPACK EUROPE The 21st edition of Pharmapack Europe will showcase the evolution and revolution in packaging and drug delivery solutions. The combination of a huge exhibition and comprehensive conference programme provides a unique opportunity for networking and partnering.

The comprehensive event programme for Europe's dedicated annual pharmaceutical packaging and drug delivery conference (7–8 February, Paris Expo Porte de Versailles) will update participants on the latest developments in the sector with key note speeches from leading industry figures, a symposium, and educational workshops. Presentations at the learning lab will explore regulatory changes and impacts; address challenges in packaging and device de-

velopment (including biologics, materials, sustainability, and maintaining consistent quality); and demonstrate how new patient-centric innovations in drug delivery can revolutionise lives and improve treatment adherence. Start-Up Pitch, a new event at Pharmapack Europe 2018, will offer early stage companies a unique opportunity to present their ideas to industry experts.

Pharmapack Europe will feature the latest industry innovations in pharma-

ceutical packaging and drug delivery for small molecules and the expanding area of biologics, the latter representing 70% of drugs currently under development. Speakers at the conference will discuss key factors for successful collaboration on pharmaceutical packaging development and integrated designs of drug delivery platforms for biologics, as well as case studies on delivery options for injectable drugs. Connectivity in drug delivery solutions along with innovations in packaging will be showcased.

In 2018, a new Start-up Hub will allow young companies to showcase their new technologies and pitch them to pharma and biopharma executives, and provide partnering opportunities between potential customers and investors. The Start-up Hub and Start-up Pitch are organised in collaboration with Early Metrics, the pan-European rating agency for start-ups and innovative SMEs. ■

Meet partners

GREETING The pharmaceutical packaging and drug delivery industry is on the crest of a new wave of innovation and opportunity. In the 21st year of Pharmapack Europe, we have once again developed an extensive programme to provide the industry with in-



sights from leading industry experts, practical guidance and workshops on challenges and opportunities, and networking and collaboration opportunities to enable visitors to share knowledge and experience to drive business forward. We kindly invite you to join us in Paris, together with 5290+ industry colleagues from all over the world.

Anne Schumacher
 Brand Director
 Pharmapack Europe
 UBM EMEA

› QUICK FACTS

IN 2017

- › 5,290+ visitors
- › 411+ exhibitors
- › Over 100 countries represented

CONTACT & Registration

Pharmapack team
 pharmapack@ubm.com
<http://bit.ly/2z07bP9>

Drug Delivery & Packaging Pharmapack

INNOVATION • NETWORKING • EDUCATION

EXHIBITION & CONFERENCE 7-8 FEBRUARY 2018 PARIS EXPO, PORTE DE VERSAILLES

Pharma's dedicated packaging & drug delivery event



INNOVATION

- Innovation Gallery
- Pharmapack Awards
- Innovation Tours
- Pharmapack Start-up Hub



NETWORKING

- Networking Areas & Events
- International Meetings Programme



EDUCATION

- Conference
- Symposium
- Workshops
- Learning Lab

FREE
to attend!

REGISTER NOW!

Follow
the link:
bit.ly/2yk2Ndd



#PharmapackEU



UBM

NEWS, WHITEPAPERS
& EVENT PROGRAMME AT
WWW.PHARMAPACKEUROPE.COM



2 March, 2018
Fraunhofer-Forum Berlin,
Berlin, Germany

SMEs in the spotlight

BERLIN CONFERENCE ON LIFE SCIENCES In its 11th edition, the one-day conference will highlight European small and medium-sized companies that are developing new therapeutics or diagnostics to fight antimicrobial resistance. Stakeholders in business, science, policy, and the finance sector will discuss major challenges faced by SMEs in the AMR arena.

How to bring novel antimicrobials and diagnostics from lab to market? How to finance risky clinical development? Which regulatory frameworks do exist for new antibiotics and diagnostics? Which incentives best support business models? Small and medium-sized en-

terprises (SMEs) constitute the major innovation engine in the AMR arena with the most significant pipelines of novel antimicrobials and diagnostics targeting multidrug-resistant bacteria. Although European biotech companies with AMR activities raised more than €200m this year (see p. 6), sustainable business models and market prospects are still challenging.

At the same time, a series of global initiatives were started: the Interagency Consultative Group (IACG) established by the United Nations; the Global R&D Hub resulting from the 2017 G20 summit; international multimillion-euro funding bodies such as CARB-X and the Global Antibiotic Research and Development Partnership (GARDP); the AMR Call to Action initiative, and the InnoFin Infectious Disease program financed by the European Investment Bank. These initiatives are particularly

welcomed by SMEs; however, they call for implementing further supportive instruments. In November, the European BEAM Alliance, which represents 40 biotech companies involved in AMR drug development, published a position paper with ten recommendations for PUSH and PULL mechanisms.

Berlin-based BIOCOM AG together with the SME association and the Fraunhofer Society, invites key players to the Berlin Conference in March 2018. The conference will provide a discussion platform to address the specific challenges faced by SMEs with more than 40 speakers representing all facets of the industry: companies (Janssen Diagnostics, Basilea, Polyphor, BioVersys, SpinDiag, Curetis, MeMed); start-ups (AGileBiotics, PhagoMed, Oppilotech, Vaxdyn); funding bodies (CARB-X, GARDP, Find Diagnostics); investors (Forbion Capital, European Investment Bank); and academic experts from the AMR centre and the Universities of Antwerp and Edinburgh.

The afternoon will feature pitching opportunities for investors, funders and start-ups. Posters highlighting promising R&D projects will be exhibited throughout the day. The event is further supported by the EU-funded European Gram Negative Anti-Bacterial Engine (ENABLE) consortium, Boehmert & Boehmert, and the British Department of International Trade.

› QUICK FACTS

Why attend?

1,300+ attendees since 2008; 40+ high-level speakers in the AMR field (therapeutics & diagnostics); poster session; Start-up-pitch

Registration

Early bird rates available as well as special rates for BEAM Alliance members and academics. Please visit: www.berlin-conferences.com

11th Berlin Conference on Life Sciences

Novel Antimicrobials and AMR Diagnostics



Kevin Outterson
Executive Director
CARB-X



Jean-Pierre Paccaud
Director of Business
Development
GARDP



Jorge Villacian
Chief Medical Officer
Janssen Diagnostics,
Pharmaceutical R&D,
Johnson & Johnson



Achim Plum
Chief Business Officer
CURETIS N.V.



Catharina Boehme
Chief Executive Officer
Foundation for Innovative
new Diagnostics (FIND)



Glenn Dale
Head of Early Development,
Antimicrobials
Polyphor Ltd



Herman Goossens
Vaccine & Infectious Disease
Institute
University of Antwerp



Mark Jones
Head of Project Management/
Head of Microbiology
Basilea Pharmaceutica Ltd



Alexander Belcredi
Chief Executive Officer &
Co-Founder
PhagoMed



Henri-François Boedt
Senior Loan Officer
Growth Capital &
Innovation Finance,
European Investment Bank

2 March 2018, Berlin, Germany

The 11th Berlin Conference on Life Sciences provides a discussion platform for addressing the specific challenges of small and medium-sized enterprises (SME) in developing novel antimicrobials and AMR diagnostics. Join an exclusive event with high-level representatives from policy, academia, industry and the finance sector. Registration and programme at: www.berlin-conferences.com

Sponsor:



Supporting Partners:



Media Partner:





BIO-EUROPE SPRING®
MARCH 12-14, 2018 // AMSTERDAM, THE NETHERLANDS

12-14 March, 2018
Amsterdam RAI Convention Center
Amsterdam, the Netherlands

“Who’s who” is here

BIO-EUROPE SPRING The 12th BIO-Europe Spring® international partnering conference meets in Amsterdam 12-14 March, 2018. This premier annual event held in Europe’s most innovative biopharma clusters, brings together executive decision makers to access in-licensing and investment opportunities in one-to-one, private business development partnering meetings.

The 12th annual BIO-Europe Spring international partnering conference will be held once again in Amsterdam, the Netherlands. The event is highly regarded among companies across the life sciences value chain, from large biotech and pharma companies to financiers and innovative start-ups.

BIO-Europe Spring offers powerful opportunities to network with the right partners, with over 2,500 attendees

from 1,400 companies and 54+ countries. With a focus on European innovation and global collaboration, the event is the premier springtime partnering conference bringing together a “who’s who” from biotech, pharma, and finance in the most innovative biopharma clusters in Europe. The event is also highly regarded for the variety and high calibre of presenting companies, ranging from academic innova-

tors and start-up biotech companies to mid-size pharma and biotech, which bring their innovative technologies, therapies, and solutions with the goal of securing development and commercialisation partners. BIO-Europe Spring also features a diverse list of industry leaders speaking at workshops and on panels.

Leading pharmaceutical companies – including all of the big names in pharma – sponsor the event, sending teams of scouts to engage with new and innovative products. Informal networking events held in stunning local venues lend further dealmaking opportunities. “Holland boasts one of the most concentrated life sciences regions in the world,” said Anna Chrisman, Managing Director of EBD Group and KNect365 Life Sciences. The 2017 event boasted over 15,000 scheduled one-to-one meetings with 3,500+ licensing opportunities posted. ■

World-class!

GREETING Join us at BIO-Europe Spring to expand your network and engage with the right partners. The event attracts a diverse range of high-quality companies presenting licensing opportunities directly to potential partners, resulting in alliances that



literally change the world. Home to 3,000+ biotech, pharma, and medtech companies and research organisations, including major multinationals like MSD, Amgen, Genmab, Astellas, GlaxoSmithKline and Medtronic, the Netherlands is a world-class destination offering opportunities for innovative partnering. See you in Amsterdam in the spring!

Anna Chrisman
Managing Director
EBD Group and KNect365 Life Sciences

QUICK FACTS

ONLINE REGISTRATION

Please visit: ebdgroup.knect365.com/bioeurope-spring/
The Early Bird Discount is available through 19 January, 2018.

PRE-EVENT COURSE

On 10-11 March, you can attend the course “Negotiation Masterclass – Improving the Probability of Success” (additional registration fee).

12TH ANNUAL INTERNATIONAL PARTNERING CONFERENCE

BIO-EUROPE SPRING®

AMSTERDAM, THE NETHERLANDS // MARCH 12-14, 2018

Meet and partner with Europe's most innovative biotech clusters.

Save **EUR 200**
Early bird deadline
is January 19

BIO-Europe Spring® is the premier springtime partnering conference bringing together a "who's who" from biotech, pharma and finance in the most innovative biopharma clusters in Europe.

What to expect:

- 13,000+ one-to-one partnering meetings
- 3,500+ licensing opportunities to access
- 2,600+ international executives from biotech, pharma, and finance
- 1,500+ companies representing 50+ countries
- 120 biotech, pharmaceutical, next generation and academic innovator presentations
- 70 C-level speakers on plenary sessions and business development workshops
- 65 exhibitors in the high-traffic heart of the conference

Produced by

EBD
GROUP

Supported by

Bio Biotechnology
Innovation
Organization

FIND OUT MORE:
ebdgroup.com/bes



A joint conference by



Academy
Your gateway
to information, courses

TRANSLATIONALE
MEDIZIN &
PHARMAKOLOGIE

Fraunhofer
IME

Co-sponsored by



13–14 March, 2018
Steigenberger Hotel
Berlin, Germany

Innovations on top

NANO AND MICROFORMULATIONS – JOINT CONFERENCE Today, nanomedicine has become a global area of investigation for both academia and the pharmaceutical industry. The new generation of therapeutics is designed to target only the source of the disease – the malignant tissues.

To deliver sufficient quantities of a drug to their pharmacological target, scientists already use nanocarriers, which release their cargo at the target site.

How to manufacture, characterise, and control the drug-release mechanism for the next generation of nanomedicines is the focus of investigation at the Research Center for Translational Medicine and Pharmacology (TMP) in Frankfurt, a collaboration between the Fraun-

hofer-Institute for Molecular Biology and Applied Ecology, and Goethe University. Researchers also hope to identify critical quality attributes and establish predictive models for in vivo applications.

An international team of scientists led by Dr. Matthias G. Wacker developed an apparatus to analyse the release behavior of micro and nanodispersions under standardised conditions. This so-called dispersion releaser technology uses a dialysis cell that can be combined with compendial equipment. It can be easily integrated in formulation development and quality control. Besides the efficient separation of the drug substance and a reduced sedimentation during the dialysis process, the dispersion releaser ensures compliance with international standards – although there is a lack of consistent and reliable standards so far to test micro and nanodispersions. It also makes measurements under physiological conditions possible and therefore allows predictions for subsequent therapy. First prototypes of the new system have been tested successfully with several drug substances. ■

Get nano!

GREETING *As nano technology has become increasingly important for global industries, more research is required in this area to effectively translate innovations into products. Nanopharmaceuticals and medical devices take advantage of advanced manufacturing technology and functionalised biomaterials. In some cases, however, nanomedicines may present unexpected challenges in manufacturing and characterisation – and even pose a potential threat to human health and the environment.*



Thus, to learn more about current technologies in the field of Nano Formulation, join us – the ECA, the Loewe Center of Translational Medicine and the Fraunhofer Institute for Molecular Biology and Applied Ecology (IME) – at the Nano and Micro Formulations conference. This comprehensive programme will address pressing legal and scientific issues: how to develop novel nanoproducts; characterise them for submission or registration; and deal with safety concerns. Take this unique opportunity to meet with your colleagues, our guest speakers, and members of regulatory bodies.

Axel H. Schroeder
Operation Director,
Concept Heidelberg

› QUICK FACTS

Registration

www.gmp-compliance.org
Register before December 31 and get a €200 discount

Highlights

- › Drug Release Testing
- › Development and Characterisation
- › Regulatory Requirements
- › Quality Considerations
- › Different Case Studies

Nano and Micro Formulations

Bringing together Science, Authority and Industry

13/14 March 2018, Berlin, Germany



Scan code to learn more



Nanotechnology has become increasingly important for global industries. But how can innovations be effectively translated into products? Join us, the ECA, the Loewe Center of Translational Medicine and the Fraunhofer Institute for Molecular Biology and Applied Ecology (IME) at the conference Nano and Micro Formulations to find out more about current and new technologies in the field of Nano Formulation. We will address the pressing concerns over how to develop novel nanoproducts, how to characterize them for submission or registration and how to deal with safety concerns. Use this unique possibility to discuss the legal and scientific aspects with colleagues, speakers and regulatory bodies.

Find out more at www.gmp-compliance.org/nanomicroformulations.

A joint conference of



Co-sponsored by



Media Partner:





SWISS 
BIOTECH™
 National Thematic Network

**3 May 2018, Swiss Biotech Day
 Congress Centre Basel
 Basel, Switzerland**

Start a new decade

SWISS BIOTECH DAY The Swiss Biotech Day has long become the standard annual get-together for the Swiss biopharmaceutical industry. On 3 May 2018 entrepreneurs, investors, researchers, analysts, political decision-makers, and industry stakeholders will meet in Basel, celebrating the 20th anniversary of the Swiss Biotech Association.

The Swiss Biotech Day (SBD) is constantly growing: 2017 was a record-breaking year, with more than 530 participants. Next year more than 600 experts from more than 20 countries are expected to meet in Basel. During this annual get-together the Swiss Biotech Association will celebrate its 20th anniversary.

There are only a few spaces in the world where so many life sciences jobs

are concentrated in one place with the density seen in Basel. From world-leading research groups, biotech entrepreneurs, start-ups and patent specialists – the region covers the entire value chain. That's why the Swiss Biotech Day 2018 will once again take place in the vivid heart of the Swiss life sciences industry.

On 3 May 2018, senior executives from Swiss and European biotech companies

and senior scientists from leading academic institutions are invited to come together at the Congress Centre Basel. Each year, the event traditionally begins with the General Assembly of the Swiss Biotech Association (SBA), which currently has more than 200 member companies representing the interests of SMEs within the biotechnology sector. In 2018, the Assembly will be followed by a keynote address from Vasant Narasimham, assigned CEO of Novartis. Next, the Swiss Biotech Report 2018 will be released, providing an opportunity for interesting discussions on potential future developments within the Swiss biotechnology field.

During the afternoon, partners of Swiss Biotech Day will present parallel sessions offering insights into specific life sciences topics such as analyses and predictions for publicly listed biotech companies, and financing opportunities in the Analyst and Investor track. ■

Get together!

GREETING *As newly appointed Chief Executive Officer of the Swiss Biotech Association, I am very happy to invite you to the Swiss Biotech Day 2018 and to celebrate the 20th anniversary of the Swiss Biotech Association. The SBD has proven to be a lot more than the Annual General*



Assembly of the Swiss Biotech Association. It has become one of the key meeting points for biotech entrepreneurs, investors, researchers, analysts, political decision makers, and industry stakeholders in Switzerland.

In 2018, the Swiss Biotech Day will end with the celebration of the 20th anniversary of the Swiss Biotech Association. Join us in Basel and celebrate with us!

Michael Altorfer

Assigned CEO, Swiss Biotech Association (effective 1 January 2018)

QUICK FACTS

REGISTRATION

www.swissbiotechday.ch
 Phone: +41-43-508-1121
register@swissbiotechday.ch

Highlights

- Keynote by Vasant Narasimhan, assigned CEO, Novartis
- Swiss Biotech Report 2018
- One-on-one partnering
- Exhibitions

SWISS BIOTECH DAY 2018

The leading Life Sciences Conference in Switzerland and Annual General Assembly of the Swiss Biotech Association



3 MAY 2018
Basel Congress Center

Join the Swiss Biotech Day, the leading biotechnology conference in Switzerland. Now in its 20th year, the event is not just the place to be for members of the Swiss Biotech Association, who traditionally meet there for the association's Annual General Assembly. As always, the event brings together entrepreneurs, investors, researchers, analysts, political decision makers and industry stakeholders.


Don't miss the keynote by the assigned CEO of Novartis, Vasant Narasimhan, and meet around 600 experts from across Europe.

All information on programme, exhibitors, sponsoring and registration can be found at www.swissbiotechday.ch.

Sponsors:



Supporting Partners:




Media Partners:



Organised by:





20–21 June, 2018
Koelnmesse,
Cologne, Germany

Focus on chemicals

CHEMSPEC EUROPE 2018 This fine and speciality chemicals exhibition is a key event for manufacturers, suppliers, and distributors of fine and speciality chemicals to meet with purchasers and agents.

Chemspec Europe is renowned for its specialised focus on the fine and speciality chemicals industry. The 33rd edition takes place at Koelnmesse in Cologne, Germany, from 20–21 June 2018.

The show provides its attendees with access to blue chip and SME suppliers from around the globe, covering the whole spectrum of custom, fine and speciality chemicals for various applications, including pharma, agriculture, bio-based chemicals and biocatalysts, food and drink, cosmetics, household and industrial cleaning, water treat-

ment, adhesives and sealants, colourants and dyestuffs, polymers, and much more.

With a total of 401 exhibitors from 29 countries and 6,476 attendees from all over the world, the previous Chemspec Europe, held 2017 in Munich, was a big success.

With the REACH deadline approaching and buzzwords like “continuous flow chemistry” prompting extensive discussions, the next Chemspec Europe, held in Cologne, will, once again, be a central meeting point for international industry professionals to exchange views on current trends and expand reliable networks between manufacturers, suppliers, commodity traders, distributors, agents, purchasers, and business partners.

Discussions, exchange of expertise, and R&D are an integral part of Chemspec Europe. Various conferences on a wide range of subjects – from regulatory and pharma outsourcing to current market developments – are held alongside the exhibition. All conferences are free to attend for participants at Chemspec Europe. ■

Welcome!

GREETING *On behalf of the organisers of Chemspec Europe (20–21 June 2018, Cologne, Germany), I welcome you to our event, which covers the most compre-*



hensive range of fine and speciality chemicals, including bio-based chemicals and biocatalysts. Chemspec Europe offers its visitors the possibility to meet with some 400 international suppliers. Extensive networking opportunities and a large number of conference sessions enable new partnerships and stimulate exchange of expertise. With its extensive product portfolio for a wide variety of different sectors, the event is a platform for synergies and innovation, and thus for new business opportunities – particularly for high potential sectors such as biotechnology.

With its international audience, Chemspec Europe reflects the global scale and structure of the fine and speciality chemicals industry. The show offers excellent sourcing and trading opportunities and a place to network and learn about the complex mechanisms of this innovative industry sector.

Nicola Hamann,
Managing Director,
Mack Brooks Exhibitions Ltd

› QUICK FACTS

Contact

Chemspec Europe
info@chemspeceurope.com
Phone: +44 (0)1727 814 400

Venue

Koelnmesse
Hall 8, Entrance North
Messeplatz 1
50679 Cologne, Germany



The fine & speciality chemicals exhibition

The industry's premier sourcing and networking event

Some 400 international exhibitors offer bespoke solutions and specific substances to enhance products or develop new chemical solutions.

Fine and speciality chemicals for various industries:

- pharmaceuticals • agrochemicals • petrochemicals
- cosmetics • adhesives & sealants • paints & coatings
- polymers • biotechnology • colourants & dyestuffs
- food & drink • industrial cleaning • reprography & printing • water treatment and much more.



Top conferences and workshops offer valuable insights into ongoing R&D projects!

Agrochemical Lecture Theatre
Chemspec Careers Clinic
Pharma Lecture Theatre
Regulatory Services Lecture Theatre
RSC Lecture Theatre
Innovative Start-ups

Koelnmesse
Cologne, Germany

20 - 21 JUNE 2018

www.chemspeceurope.com